Oral mRNA Nanotherapy for Bleeding Disorder
口服 mRNA 纳米疗法治疗出血性疾病
基本信息
- 批准号:10750040
- 负责人:
- 金额:$ 6.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAmino Acid TransporterBiodistributionBiological AvailabilityBlood Chemical AnalysisBlood Coagulation DisordersBlood Coagulation FactorBlood coagulationCOVID-19CirculationClinicClinicalCoagulation ProcessDevelopmentDiffusionDoctor of PhilosophyDoseEpitheliumErythropoietinEvaluationFactor VIIIFormulationGenerationsGenetic DiseasesGoalsHalf-LifeHematocrit procedureHematologyHemophilia AHepatocyteHumanIn VitroInfusion proceduresInsulinIntravenous infusion proceduresLaboratoriesLeadLightLipid ChemistryLipidsLiverMeasuresMediatingMedicalMessenger RNAMicellesModalityModelingMonitorMucous body substanceMusNanotechnologyNatureOralOral AdministrationOrganPatientsPatternPermeabilityPropertyProtein EngineeringProtein OverexpressionProteinsProtonsRNA deliveryRNA vaccineRecombinant ProteinsRecombinantsReplacement TherapyReportingRouteSafetySeriesStainsTestingTherapeuticTight JunctionsTimeTrainingTranslationsTransportationTreatment EfficacyWorkabsorptionbiomaterial compatibilitycommon treatmentcompliance behaviorcytotoxicityenzyme replacement therapyimprovedin vitro activityin vivoinjection/infusioninnovationintestinal epitheliumlipid nanoparticlemRNA TranslationmRNA deliverymouse modelnanoparticle deliverynanotechnology platformnanotherapynovelnovel therapeuticsprotein expressionscreeningside effecttherapeutic proteintranscytosis
项目摘要
ABSTRACT
Protein replacement therapy has been a cornerstone in treating genetic diseases (e.g., hemophilia) with loss or
reduction of the function of a particular protein, by using recombinant proteins or recombinant engineered
proteins. However, most protein therapeutics have short circulation lives, and thus require frequent invasive
infusion to maintain their therapeutic efficacy. For example, the most common treatment for hemophilia A caused
by a deficiency of blood clotting factor VIII (FVIII) is factor concentrate replacement, which is associated with
burdensome frequent intravenous infusion. To address the unmet medical need of hemophilia, the major
objective of this project is to develop a non-invasive oral mRNA delivery nanoplatform for durable protein
replacement therapy requiring infrequent dosing. Synthetic mRNA has shown enormous potential for biomedical
applications, with mRNA vaccines already clinically approved for COVID-19. Various delivery strategies have
been developed to improve mRNA translation; however, an ongoing challenge of mRNA therapy is managing
the transient efficacy due to its relatively short half-life, and oral mRNA delivery remains elusive. In my previous
work, I have identified a unique poly(zwitterion)-lipid-based micelle platform that can cross the intestinal epithelial
barrier and lead to a very potent oral bioavailability of biomolecules such as insulin. Recently, I have also
discovered a new type of ionizable lipids that can extend the duration of mRNA-mediated protein expression. In
this F32 project, I propose to combine the epithelium-crossing poly(zwitterion)-lipids and the unique ionizable
lipids to develop an innovative mRNA delivery platform for oral, durable replacement therapy of bleeding
disorders. In Aim 1, I will synthesize new poly(zwitterion)-lipids and ionizable lipids and generate a series of new
mRNA lipid nanoparticles (LNPs), and systematically investigate their effects on oral transcytosis and the
durability of protein expression in vitro and in vivo. In Aim 2, we will select the top-performing LNPs for oral
delivery of FVIII mRNA and evaluate the FVIII mRNA nanotherapy in healthy and hemophilia mouse models.
With the successful completion of this project, we expect that the oral durable mRNA delivery strategy will provide
a more effective and robust therapy for hemophilia and other bleeding disorders.
摘要
蛋白质替代疗法一直是治疗遗传性疾病(如血友病)的基石。
通过使用重组蛋白质或重组工程来降低特定蛋白质的功能
蛋白质。然而,大多数蛋白质疗法的循环寿命短,因此需要频繁的侵入性治疗。
输液以维持其治疗效果。例如,血友病A最常见的治疗方法是
凝血因子VIII(FVIII)是凝血因子的替代,与凝血因子的缺乏有关
繁重的频繁静脉输液。为了解决血友病未得到满足的医疗需求,主要的
本项目的目标是开发一种非侵入性口服信使核糖核酸传递耐久蛋白的纳米平台
需要很少用药的替代疗法。人工合成的信使核糖核酸在生物医学方面显示出巨大的潜力
应用,信使核糖核酸疫苗已经被临床批准用于新冠肺炎。各种交付策略都有
被开发来改善信使核糖核酸的翻译;然而,信使核糖核酸治疗的一个持续的挑战是管理
由于其相对较短的半衰期和口服信使核糖核酸的传递,其短暂的疗效仍然难以捉摸。在我之前的
工作中,我发现了一种独特的聚(两性离子)-基于脂质的胶束平台,它可以穿过肠道上皮
并导致胰岛素等生物分子具有非常强的口服生物利用度。最近,我也
发现了一种新型的可电离脂质,可以延长信使核糖核酸介导的蛋白质表达的持续时间。在……里面
在这个F32项目中,我建议将跨越上皮的聚(两性)脂和独特的可电离
Lipids将开发一种创新的信使核糖核酸传递平台,用于口服、持久的止血替代疗法
精神错乱。在目标1中,我将合成新的两性离子脂类和可电离类脂,并生成一系列新的
信使核糖核酸脂纳米粒(LNPs),并系统地研究了它们对口腔转胞作用的影响和
蛋白质在体外和体内表达的持久性。在目标2中,我们将选出表现最好的LNPs进行口语
在健康和血友病小鼠模型中传递FVIII信使核糖核酸并评价FVIII信使核糖核酸纳米治疗。
随着这个项目的成功完成,我们预计口服持久信使核糖核酸传递策略将提供
对血友病和其他出血性疾病更有效和更有力的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiangfei Han其他文献
Xiangfei Han的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Targeting the Amino Acid Transporter SLC7A5 for Pulmonary Fibrosis
靶向氨基酸转运蛋白 SLC7A5 治疗肺纤维化
- 批准号:
10630480 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Determinants of amino acid transporter oligomerization in membranes
膜中氨基酸转运蛋白寡聚的决定因素
- 批准号:
10725968 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches
氨基酸转运蛋白 SLC38A5 作为 TNBC 的药物靶点:用遗传和药理学方法进行评估
- 批准号:
10576760 - 财政年份:2022
- 资助金额:
$ 6.95万 - 项目类别:
Targeting the Amino Acid Transporter SLC7A5 for Treatment of Pulmonary Fibrosis
靶向氨基酸转运蛋白 SLC7A5 治疗肺纤维化
- 批准号:
10683793 - 财政年份:2022
- 资助金额:
$ 6.95万 - 项目类别:
Structural and functional elucidation of L-type amino acid transporter under lipid environment
脂质环境下L型氨基酸转运蛋白的结构和功能阐明
- 批准号:
21K15031 - 财政年份:2021
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of new BNCT sensitizer based on molecular chirality recognition of amino acid transporter LAT
基于氨基酸转运蛋白LAT的分子手性识别开发新型BNCT敏化剂
- 批准号:
21K19348 - 财政年份:2021
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Elucidation of tissue-repair response in lung fibrosis by focusing on the amino acid transporter SLC15A3
通过关注氨基酸转运蛋白 SLC15A3 阐明肺纤维化中的组织修复反应
- 批准号:
21K16155 - 财政年份:2021
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Hybridized structure- and ligand- based drug discovery approaches targeting ASCT2, an amino acid transporter critical for upregulated cell proliferation in numerous cancer types
针对 ASCT2 的基于杂交结构和配体的药物发现方法,ASCT2 是一种氨基酸转运蛋白,对于多种癌症类型的细胞增殖上调至关重要
- 批准号:
10333203 - 财政年份:2020
- 资助金额:
$ 6.95万 - 项目类别:
Exploration of new therapeutic strategy targeting amino acid transporter in renal cell carcinoma
肾细胞癌靶向氨基酸转运蛋白治疗新策略的探索
- 批准号:
20K18108 - 财政年份:2020
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigating the Physiological Role of Cl- permeation through Excitatory Amino Acid Transporter 1 (
通过兴奋性氨基酸转运蛋白 1 研究氯渗透的生理作用(
- 批准号:
552252-2020 - 财政年份:2020
- 资助金额:
$ 6.95万 - 项目类别:
University Undergraduate Student Research Awards














{{item.name}}会员




